全文获取类型
收费全文 | 37873篇 |
免费 | 2586篇 |
国内免费 | 553篇 |
专业分类
耳鼻咽喉 | 662篇 |
儿科学 | 597篇 |
妇产科学 | 733篇 |
基础医学 | 5477篇 |
口腔科学 | 607篇 |
临床医学 | 3098篇 |
内科学 | 8427篇 |
皮肤病学 | 1363篇 |
神经病学 | 2680篇 |
特种医学 | 1797篇 |
外科学 | 4986篇 |
综合类 | 663篇 |
一般理论 | 16篇 |
预防医学 | 1644篇 |
眼科学 | 1071篇 |
药学 | 3364篇 |
1篇 | |
中国医学 | 424篇 |
肿瘤学 | 3402篇 |
出版年
2023年 | 241篇 |
2022年 | 716篇 |
2021年 | 1194篇 |
2020年 | 603篇 |
2019年 | 964篇 |
2018年 | 1112篇 |
2017年 | 848篇 |
2016年 | 1127篇 |
2015年 | 1494篇 |
2014年 | 1806篇 |
2013年 | 2069篇 |
2012年 | 3001篇 |
2011年 | 3031篇 |
2010年 | 1801篇 |
2009年 | 1536篇 |
2008年 | 2217篇 |
2007年 | 2080篇 |
2006年 | 1867篇 |
2005年 | 1820篇 |
2004年 | 1526篇 |
2003年 | 1449篇 |
2002年 | 1310篇 |
2001年 | 881篇 |
2000年 | 783篇 |
1999年 | 715篇 |
1998年 | 284篇 |
1997年 | 256篇 |
1996年 | 228篇 |
1995年 | 194篇 |
1994年 | 171篇 |
1993年 | 114篇 |
1992年 | 361篇 |
1991年 | 271篇 |
1990年 | 295篇 |
1989年 | 287篇 |
1988年 | 283篇 |
1987年 | 235篇 |
1986年 | 199篇 |
1985年 | 181篇 |
1984年 | 150篇 |
1983年 | 122篇 |
1982年 | 90篇 |
1981年 | 81篇 |
1980年 | 79篇 |
1979年 | 134篇 |
1978年 | 88篇 |
1977年 | 79篇 |
1975年 | 68篇 |
1973年 | 62篇 |
1972年 | 71篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
991.
992.
993.
994.
Ju‐Yeon Cho Won Sohn Yong‐Han Paik Geum‐Youn Gwak Moon Seok Choi Joon Hyeok Lee Kwang Cheol Koh Seung Woon Paik Chan Guk Park 《Journal of viral hepatitis》2020,27(9):951-954
The aim of this study was to investigate the on‐treatment kinetics of quantitative HBsAg during entecavir therapy to predict the treatment period needed to achieve functional cure. From a cohort of 1009 CHB treatment‐naïve patients who were started on entecavir, the kinetics of quantitative HBsAg decline was assessed in 410 patients by a linear mixed model. The difference in the kinetics of quantitative HBsAg was determined based on the HBeAg positivity, HBeAg seroclearance and presence of baseline liver cirrhosis. Among the 410 patients, 213 patients (52.0%) were HBeAg‐positive and 217 patients (66.1%) were male with a median age of 48 years. During a median follow‐up of 53.5 months, the quantitative HBsAg level showed a slow but consistent decrease. The expected log qHBsAg levels as a function of time during entecavir treatment in HBeAg(+) and HBeAg(?) patients were 3.4773‐0.0039 × Months and 3.1853‐0.0036 × Months, respectively. The estimated time to clearance of quantitative HBsAg in our study was greater than 74.1 years in HBeAg‐positive patients and 73.5 years in HBeAg‐negative patients. The calculated time to achieve functional cure is lifelong without regard to HBeAg seroclearance or presence of liver cirrhosis. The mathematical modelling from a long‐term follow‐up of chronic hepatitis B patients on entecavir shows that HBsAg clearance requires decades of treatment. Thus, lifelong therapy is inevitable in entecavir‐treated patients to achieve functional cure. 相似文献
995.
996.
Jae Kyun Choi Soomin Ahn Jai Young Cho YoungRok Choi Ho‐Seong Han Boo‐ok Jang Gwang Hyeon Choi Eun Sun Jang Jin‐Wook Kim Sook‐Hyang Jeong 《Transplant infectious disease》2020,22(3)
Acute hepatitis E virus (HEV) infection could lead to acute liver failure (ALF), which requires liver transplantation (LT). HEV infection could progress to chronic infection in an immunosuppressed host. De novo autoimmune hepatitis (AIH) is a rare occurrence of AIH during post‐LT immunosuppressive therapy in patients who underwent LT due to not AIH but some other etiology. Here, we report the first case of ALF due to HEV infection, the recurrence of HEV after LT that responded to ribavirin therapy, and then the development of de novo AIH showing a complete response to glucocorticoid therapy but multiple relapses after steroid withdrawal. This peculiar case suggests that HEV could have a pathogenic role in the development of the de novo AIH; additionally, this case report could help clinicians make therapeutic decisions in the post‐LT condition. 相似文献
997.
998.
999.
1000.